Dr. Ajay Kuriyan from University of Rochester and Dr. Shriji Patel from Vanderbilt University join the show for a journal club focusing on 3 recent publications in major ophthalmology journals, including a prospective study examining ranibizumab and aflibercept for wet AMD, subanalysis examining factors associated with better anatomic and visual improvements in Protocol T and a paper detailing the natural history of central serous retinopathy.
Financial Disclosures: Dr. Kuriyan is a consultant for Regeneron, Allergan, Alimera, and Valeant and receives grant funding from Second Sight. Dr. Patel has no disclosures. Dr. Sridhar is a consultant for Allergan, Alimera Science, and Alcon Laboratories.
CME Information
Release: March. 8, 2019; expires March. 8, 2022
Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.